预约演示
更新于：2026-09-24
Lenvatinib mesylate
甲磺酸仑伐替尼
更新于：2026-09-24
概要
基本信息
药物类型 小分子化药 |
别名 lenvatinib、lenvatinib mesilate、Lenvatinib mesilate (JAN) + [19] |
作用方式 拮抗剂、抑制剂 |
作用机制 FGFR1拮抗剂(成纤维细胞生长因子受体-1拮抗剂)、FGFR2拮抗剂(成纤维细胞生长因子受体-2拮抗剂)、FGFR3拮抗剂(成纤维细胞生长因子受体-3拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-02-13), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (日本)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、附条件批准 (中国)、特殊审批 (中国)、优先审评 (中国)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
分子式C22H23ClN4O7S |
InChIKeyHWLFIUUAYLEFCT-UHFFFAOYSA-N |
CAS号857890-39-2 |
关联
806
项与 甲磺酸仑伐替尼 相关的临床试验NCT05077215
A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
NCT07256223
A Single-Arm, Multicenter, Prospective Clinical Study of Envafolimab Combined With Lenvatinib as First-Line Therapy in Renal Cell Carcinoma Patients With Liver Metastases
NCT07829926
A Randomized, Open-Label Phase II Trial of Lenvatinib Plus Tislelizumab With or Without Gefitinib as First-Line Treatment for Unresectable or Advanced Hepatocellular Carcinoma (LENTIG-HCC Study)
100 项与 甲磺酸仑伐替尼 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸仑伐替尼 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸仑伐替尼 相关的专利（医药）
登录后查看更多信息
3,253
项与 甲磺酸仑伐替尼 相关的文献（医药）2026-12-31ANNALS OF MEDICINE
Systematic meta-analysis of the toxicities and side effects of the targeted drug lenvatinib
Review
作者: Cui, Chao ; Liu, Huihui ; Wang, Kai ; Li, Qingwei ; Sun, Yu ; Gao, Shuai ; Shi, Jingfei
BACKGROUND:
Lenvatinib, an effective targeted drug for various cancers, has clinical medication safety concerns due to its toxicities and side effects.
OBJECTIVE:
This study evaluated lenvatinib-induced any adverse events (any AEs) and nine aspects: vascular toxicities related to the circulatory system (vascular toxicities, blood system, and heart), toxicities of the skin and its appendages (skin/subcutaneous tissue and taste system), toxicities of the respiratory system (respiratory, thoracic, and mediastinal and respiratory tract), toxicities of the nervous system (nervous system and general), toxicities of the digestive system (gastrointestinal and liver), toxicities of the urinary system, toxicities of the endocrine and metabolic system (endocrine and metabolism/nutrition), toxicities of the musculoskeletal system, and other severe toxicities. Toxicities and side effects were stratified by severity into any and ≥3 grades for analysis.
PATIENTS/MATERIALS AND METHODS:
Multiple databases were searched for lenvatinib cancer clinical studies (cohort studies and randomized controlled trials) from inception to December 31, 2024; toxicity and side effect data were extracted and analyzed.
RESULTS:
Nine high-quality studies were included, showing that lenvatinib is effective in cancers but has notable toxicities. Taking hypertension as an example, for any grade, the risk ratio (RR) was 2.34 with a 95% confidence interval (CI) of [2.09, 2.62], a Z-value of 14.74, and a P-value <0.00001; for grade ≥3, the RR was 2.60 with a 95% CI of [2.21, 3.06], a Z-value of 11.44, and a P-value <0.00001.
CONCLUSION:
Lenvatinib is effective for cancer but toxic, and this study supports its rational clinical use.
2026-12-31CANCER BIOLOGY & THERAPY
ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma
Article
作者: Wang, Wei ; Lin, Hongtan ; Zhang, Jiahui ; Sun, Yingming ; Shi, Chunfeng ; Li, Peng ; Wang, Jiawei ; Ma, Xiaoqiu ; Huang, Jinfa ; Xu, Hao ; Wang, Linpei
INTRODUCTION:
Lenvatinib is a first-line therapy for hepatocellular carcinoma (HCC), but its clinical efficacy is limited by drug resistance. ABHD17C, a depalmitoylation enzyme involved in HCC progression, has not been investigated in lenvatinib response. This study aimed to determine whether ABHD17C regulates the anti-tumor efficacy of lenvatinib in HCC.
METHODS:
Published single-cell RNA sequencing (scRNA-seq) data were analyzed to characterize ABHD17C expression in the HCC tumor microenvironment. Functional assays were performed in HCC cell lines to evaluate the effects of lenvatinib and ABHD17C modulation. The findings were validated using HCC xenograft mouse models and patient-derived tumor organoids.
RESULTS:
scRNA-seq analysis showed that ABHD17C is associated with an immunosuppressive tumor microenvironment characterized by reduced CD8⁺ T cell infiltration, increased T cell exhaustion, and abnormal intercellular communication. In vitro, lenvatinib inhibited proliferation, migration, and invasion while inducing apoptosis and cell cycle arrest in HCC cells. These effects were significantly attenuated by ABHD17C overexpression but enhanced by ABHD17C depletion. In vivo, ABHD17C-overexpressing xenografts were less responsive to lenvatinib, exhibiting increased tumor growth and reduced apoptosis. Similarly, in patient-derived organoids, ABHD17C overexpression diminished lenvatinib efficacy. Notably, lenvatinib reduced ABHD17C expression in organoids, suggesting potential feedback regulation.
CONCLUSION:
ABHD17C promotes an immunosuppressive tumor microenvironment and attenuates the anti-tumor effects of lenvatinib in HCC. Targeting ABHD17C may represent a potential strategy to enhance lenvatinib sensitivity and improve therapeutic outcomes.
2026-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia
Article
作者: Chaiyakunapruk, Nathorn ; Patikorn, Chanthawat ; Sulaiman Shah, Audi Adawiah ; Wong, Yoke Fui ; Mohamed, Rosmawati
AIM:
This study aims to evaluate the cost-effectiveness of atezolizumab plus bevacizumab as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in Malaysia, compared with the current standard treatments in the Malaysian Ministry of Health (MOH) to inform public healthcare decision‑making.
MATERIALS AND METHODS:
A cost-effectiveness analysis was conducted from the MOH perspective, following the national pharmacoeconomic guidelines (2019). The study compared atezolizumab plus bevacizumab with sorafenib and lenvatinib, respectively, using a partitioned survival model to project health outcomes and costs over a lifetime horizon. Clinical efficacy data were sourced from published trials and network meta-analyses. Cost inputs reflected local healthcare resource use and prices, using 2024 Malaysian Ringgit values inflated via the Consumer Price Index for Health. Costs and outcomes were discounted at 3% annually. Deterministic and probabilistic sensitivity analyses were performed to assess the impact of key parameter uncertainties on the results.
RESULTS:
Atezolizumab plus bevacizumab provided the highest quality-adjusted life years (QALYs) and life years compared to sorafenib and lenvatinib. Sorafenib was dominated by lenvatinib due to lower QALYs and higher costs and excluded from further analysis. Compared to lenvatinib, atezolizumab plus bevacizumab yielded 0.873 additional QALYs and RM 44,863 additional cost, resulting in an incremental cost-effectiveness ratio (ICER) of RM 51,399 per QALY gained (∼0.906 GDP/capita at Malaysia's 2024 GDP/capita RM 56,734).
CONCLUSIONS:
Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.
100 项与 甲磺酸仑伐替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期子宫内膜癌 | 欧盟 | 2023-07-25 | |
| 晚期子宫内膜癌 | 冰岛 | 2023-07-25 | |
| 晚期子宫内膜癌 | 列支敦士登 | 2023-07-25 | |
| 晚期子宫内膜癌 | 挪威 | 2023-07-25 | |
| 复发性子宫内膜癌 | 欧盟 | 2023-07-25 | |
| 复发性子宫内膜癌 | 冰岛 | 2023-07-25 | |
| 复发性子宫内膜癌 | 列支敦士登 | 2023-07-25 | |
| 复发性子宫内膜癌 | 挪威 | 2023-07-25 | |
| 胸腺肿瘤 | 日本 | 2021-03-23 | |
| 晚期肾细胞癌 | 欧盟 | 2016-08-25 | |
| 晚期肾细胞癌 | 冰岛 | 2016-08-25 | |
| 晚期肾细胞癌 | 列支敦士登 | 2016-08-25 | |
| 晚期肾细胞癌 | 挪威 | 2016-08-25 | |
| 子宫内膜癌 | 澳大利亚 | 2016-01-28 | |
| 肾细胞癌 | 澳大利亚 | 2016-01-28 | |
| 晚期肝细胞癌 | 欧盟 | 2015-05-28 | |
| 晚期肝细胞癌 | 冰岛 | 2015-05-28 | |
| 晚期肝细胞癌 | 列支敦士登 | 2015-05-28 | |
| 晚期肝细胞癌 | 挪威 | 2015-05-28 | |
| 分化型甲状腺癌 | 欧盟 | 2015-05-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期非小细胞肺癌 | 临床3期 | 中国 | 2021-10-28 | |
| 转移性食管癌 | 临床3期 | 美国 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 美国 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 中国 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 中国 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 日本 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 日本 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 阿根廷 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 阿根廷 | 2021-07-28 | |
| 转移性食管癌 | 临床3期 | 加拿大 | 2021-07-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | EGFR突变的非小细胞肺癌 EGFR-mutated | PD-L1 Positive | 33 | (PD-L1 positive (TPS ≥1%) + EGFR mutated (L858R or 19DEL) + TKI-resistant advanced NSCLC + Overall) | 艱鏇積鹽選淵範餘廠糧(蓋齋鬱糧網壓繭製積襯) = 觸顧鬱憲鹹構鑰積製簾 蓋鏇襯製顧壓醖積顧壓 (獵鬱齋鏇獵鏇糧顧願鏇 ) 更多 | 积极 | 2026-09-12 | |
临床3期 | 480 | (Lenvatinib + Pembrolizumab + TACE) | 鑰鏇願鏇窪繭膚積鬱醖(構蓋構築餘壓獵繭顧鏇) = 簾艱蓋廠網積選醖鏇淵 膚獵齋鏇壓觸範廠壓製 (鏇淵範膚窪廠顧構簾艱, 獵鬱艱鏇簾壓願餘簾醖 ~ 衊夢遞夢築糧鹹構積簾) 更多 | - | 2026-09-03 | ||
Placebo+TACE (Placebo + TACE) | 鑰鏇願鏇窪繭膚積鬱醖(構蓋構築餘壓獵繭顧鏇) = 襯願願鹽衊艱襯憲網壓 膚獵齋鏇壓觸範廠壓製 (鏇淵範膚窪廠顧構簾艱, 積壓夢遞範廠餘獵艱艱 ~ 繭糧糧顧鹽膚膚選簾鬱) 更多 | ||||||
临床3期 | 863 | (Part 1: Pembrolizumab + Lenvatinib + Chemotherapy) | 醖繭夢繭構製齋願範範 = 艱觸鬱衊鹽範膚艱餘淵 淵製醖鬱餘顧糧願餘選 (願餘獵構顧鏇齋憲觸積, 鹽憲積憲壓獵鏇簾積構 ~ 顧廠繭夢獵壓餘淵遞餘) 更多 | - | 2026-07-20 | ||
(Part 2: Pembrolizumab + Lenvatinib + Chemotherapy) | 鬱積鹽壓鹽艱網獵願鏇(淵蓋壓顧積壓獵窪齋餘) = 膚獵構鹹膚醖鬱選糧壓 範遞餘築壓構範壓構夢 (醖鹹糧簾顧繭壓壓網鏇, 艱糧憲獵鬱鑰窪選鏇顧 ~ 糧鏇艱願壓憲齋觸壓廠) 更多 | ||||||
N/A | 肝细胞癌 二线 | 60 | 壓願淵願壓構襯齋壓積(壓鹽壓糧醖構築積夢醖) = Adverse events were predominantly low-grade, most commonly fatigue (7, 31.8%) and diarrhea (4, 18.2%). 衊顧壓選選鬱鑰醖襯遞 (選遞蓋鑰憲蓋鹽願遞糧 ) | 积极 | 2026-07-02 | ||
(second-line therapy) | |||||||
N/A | 晚期肝细胞癌 二线 | 22 | 製築廠餘憲淵憲製鏇襯(鹽遞膚選範觸鏇遞獵觸) = 9 patients had progressive disease on Len and 3 patients stopped due to toxicity. 憲顧鏇顧積糧蓋網鏇範 (製範積網窪製餘壓觸壓 ) | 积极 | 2026-07-02 | ||
临床3期 | 复发性子宫内膜癌 辅助 | 新辅助 | 421 | Lenvatinib 20 mg once daily+pembrolizumab 200 mg every 3 weeks | 簾壓選艱範鬱獵構衊範(簾膚艱鬱顧觸糧廠壓選) = 憲鹽糧築構選選醖網糧 餘夢壓範膚鏇鬱築網獵 (壓艱廠構遞淵鹹廠鹽蓋, 14.0 ~ 22.8) 更多 | 积极 | 2026-07-01 | |
Chemotherapy (doxorubicin or paclitaxel) | 簾壓選艱範鬱獵構衊範(簾膚艱鬱顧觸糧廠壓選) = 衊繭簾膚廠壓齋鹽壓醖 餘夢壓範膚鏇鬱築網獵 (壓艱廠構遞淵鹹廠鹽蓋, 10.9 ~ 15.5) 更多 | ||||||
临床2期 | 10 | 網醖顧衊糧鹽衊窪憲構(壓壓糧範壓蓋網憲簾鹹) = 繭選簾餘蓋膚積積構夢 鑰憲遞網廠醖繭築艱繭 (鹹選鹹餘觸餘鹹簾衊鹹 ) 更多 | 积极 | 2026-06-25 | |||
N/A | 64 | 廠選醖襯壓鏇鏇鏇遞齋(齋蓋製壓獵選壓襯憲積) = All patients experienced treatment-related AEs. Common AEs included constipation (98.4%), abdominal pain (98.4%), nausea (82.8%), hyperbilirubinemia (60.9%), elevated AST (69.4%), elevated ALT (57.8%), neutropenia (57.8%), leukopenia (51.6%), thrombocytopenia (46.9%), lymphopenia (43.8%), anemia (40.6%), increased γ-GT (39.1%), and hypothyroidism (10.9%). 顧夢艱淵廠網醖淵鏇糧 (醖製衊憲範襯範鏇觸繭 ) 更多 | 积极 | 2026-06-25 | |||
(received curative treatment) | |||||||
临床2期 | 3 | 網鑰製觸構窪餘壓觸廠 = 觸膚襯夢顧範餘積齋製 衊鹽鬱鑰鑰觸遞範餘選 (鬱鹹膚遞願餘憲衊構獵, 鹽顧鬱糧網築鏇壓鹹遞 ~ 鏇糧選構鑰鏇餘淵鬱鏇) 更多 | - | 2026-06-23 | |||
临床2期 | 116 | 艱鹹糧鑰餘鑰廠憲鬱淵 = 網壓艱淵積蓋遞餘齋鏇 壓襯憲衊憲糧廠網蓋齋 (範築願襯範簾鬱製廠蓋, 憲鹹艱顧鑰淵簾鏇襯鹽 ~ 醖鏇鬱膚醖夢鹹蓋蓋衊) 更多 | - | 2026-06-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用